Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2013

01.06.2013 | Epidemiology

Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ

verfasst von: Laura C. Collins, Ninah Achacoso, Reina Haque, Larissa Nekhlyudov, Suzanne W. Fletcher, Charles P. Quesenberry Jr., Stuart J. Schnitt, Laurel A. Habel

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

We aimed to identify clinicopathologic factors associated with local recurrence (LR) in a large population of DCIS patients treated with breast-conserving therapy between 1990–2001 in three health plans. Regression methods were used to estimate relative risks (RR) of LR. Among 2,995 patients, 325 had a LR [10.9 %; median follow-up 4.8 years (range 0.5–15.7)]. After adjusting for health plan and treatment, risk of LR was increased among women <45 years (RR = 2.1, 95 % CI 1.5–2.8), African-Americans (RR = 1.6; 95 % CI 1.1–2.1) and those with DCIS detected because of signs/symptoms (RR = 1.6; 95 % CI 1.2–2.0). After also adjusting for age and diagnosis year, pathologic features associated with increased LR were larger lesion size (RR = 2.9 for ≥20 low power fields of DCIS; 95 % CI 1.6–5.6) and involved (RR = 2.9; 95 % CI 1.6–5.2), or close margins (RR = 2.4; 95 % CI 1.6–3.8). Presentation with symptoms/signs was associated with increased risk of invasive recurrence; while African-American race, larger tumor size, and involved/close tumor margins were more strongly associated with increased risk of DCIS recurrence. Our findings suggest some risk factors differ for non-invasive and invasive LRs and that most factors are only moderately associated with increased LR risk. Future research efforts should focus on non-clinicopathologic factors to identify more powerful risk factors for LR.
Literatur
1.
Zurück zum Zitat Ernster VL, Ballard-Barbash R, Barlow WE et al (2002) Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 94(20):1546–1554PubMedCrossRef Ernster VL, Ballard-Barbash R, Barlow WE et al (2002) Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 94(20):1546–1554PubMedCrossRef
2.
Zurück zum Zitat Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman LJ (2011) Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat 129(1):165–173PubMedCrossRef Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman LJ (2011) Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat 129(1):165–173PubMedCrossRef
3.
Zurück zum Zitat Evans AJ, Pinder SE, Ellis IO, Wilson AR (2001) Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease? J Med Screen 8(3):149–151PubMedCrossRef Evans AJ, Pinder SE, Ellis IO, Wilson AR (2001) Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease? J Med Screen 8(3):149–151PubMedCrossRef
4.
Zurück zum Zitat Wong JS, Kaelin CM, Troyan SL et al (2006) Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 24(7):1031–1036PubMedCrossRef Wong JS, Kaelin CM, Troyan SL et al (2006) Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 24(7):1031–1036PubMedCrossRef
5.
Zurück zum Zitat Fisher ER, Dignam J, Tan-Chiu E et al (1999) Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) 8-year update of Protocol B-17: intraductal carcinoma. Cancer 86(3):429–438PubMedCrossRef Fisher ER, Dignam J, Tan-Chiu E et al (1999) Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) 8-year update of Protocol B-17: intraductal carcinoma. Cancer 86(3):429–438PubMedCrossRef
6.
Zurück zum Zitat Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362(9378):95–102PubMedCrossRef Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362(9378):95–102PubMedCrossRef
7.
Zurück zum Zitat Bijker N, Meijnen P, Peterse JL et al (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: 10-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24(21):3381–3387PubMedCrossRef Bijker N, Meijnen P, Peterse JL et al (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: 10-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24(21):3381–3387PubMedCrossRef
8.
Zurück zum Zitat Wapnir IL, Dignam JJ, Fisher B et al (2011) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103(6):478–488PubMedCrossRef Wapnir IL, Dignam JJ, Fisher B et al (2011) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103(6):478–488PubMedCrossRef
9.
Zurück zum Zitat Schnitt SJ (2010) Local outcomes in ductal carcinoma in situ based on patient and tumor characteristics. J Natl Cancer Inst Monogr 2010(41):158–161PubMedCrossRef Schnitt SJ (2010) Local outcomes in ductal carcinoma in situ based on patient and tumor characteristics. J Natl Cancer Inst Monogr 2010(41):158–161PubMedCrossRef
10.
Zurück zum Zitat Fisher B, Dignam J, Wolmark N et al (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353(9169):1993–2000PubMedCrossRef Fisher B, Dignam J, Wolmark N et al (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353(9169):1993–2000PubMedCrossRef
11.
Zurück zum Zitat Silverstein MJ, Barth A, Poller DN et al (1995) Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer 31A(9):1425–1427PubMedCrossRef Silverstein MJ, Barth A, Poller DN et al (1995) Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer 31A(9):1425–1427PubMedCrossRef
12.
Zurück zum Zitat Meijnen P, Oldenburg HS, Peterse JL, Bartelink H, Rutgers EJ (2008) Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast. Ann Surg Oncol 15(1):235–243PubMedCrossRef Meijnen P, Oldenburg HS, Peterse JL, Bartelink H, Rutgers EJ (2008) Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast. Ann Surg Oncol 15(1):235–243PubMedCrossRef
13.
Zurück zum Zitat Kerlikowske K, Molinaro A, Cha I et al (2003) Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 95(22):1692–1702PubMedCrossRef Kerlikowske K, Molinaro A, Cha I et al (2003) Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 95(22):1692–1702PubMedCrossRef
14.
Zurück zum Zitat Solin LJ, Fourquet A, Vicini FA et al (2005) Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer 103(6):1137–1146PubMedCrossRef Solin LJ, Fourquet A, Vicini FA et al (2005) Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer 103(6):1137–1146PubMedCrossRef
15.
Zurück zum Zitat Bijker N, Peterse JL, Duchateau L et al (2001) Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 19(8):2263–2271PubMed Bijker N, Peterse JL, Duchateau L et al (2001) Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 19(8):2263–2271PubMed
16.
Zurück zum Zitat Solin LJ, McCormick B, Recht A et al (1996) Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation. Cancer J Sci Am 2(3):158PubMed Solin LJ, McCormick B, Recht A et al (1996) Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation. Cancer J Sci Am 2(3):158PubMed
17.
Zurück zum Zitat Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N (2001) Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 28(4):400–418PubMedCrossRef Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N (2001) Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 28(4):400–418PubMedCrossRef
18.
Zurück zum Zitat Goldstein NS, Kestin L, Vicini F (2000) Intraductal carcinoma of the breast: pathologic features associated with local recurrence in patients treated with breast-conserving therapy. Am J Surg Pathol 24(8):1058–1067PubMedCrossRef Goldstein NS, Kestin L, Vicini F (2000) Intraductal carcinoma of the breast: pathologic features associated with local recurrence in patients treated with breast-conserving therapy. Am J Surg Pathol 24(8):1058–1067PubMedCrossRef
19.
Zurück zum Zitat Vicini FA, Kestin LL, Goldstein NS et al (2000) Impact of young age on outcome in patients with ductal carcinoma-in situ treated with breast-conserving therapy. J Clin Oncol 18(2):296–306PubMed Vicini FA, Kestin LL, Goldstein NS et al (2000) Impact of young age on outcome in patients with ductal carcinoma-in situ treated with breast-conserving therapy. J Clin Oncol 18(2):296–306PubMed
20.
Zurück zum Zitat Van Zee KJ, Liberman L, Samli B et al (1999) Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery: the effect of age. Cancer 86(9):1757–1767PubMedCrossRef Van Zee KJ, Liberman L, Samli B et al (1999) Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery: the effect of age. Cancer 86(9):1757–1767PubMedCrossRef
21.
Zurück zum Zitat Habel LA, Achacoso NS, Haque R et al (2009) Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res 11(6):R85PubMedCrossRef Habel LA, Achacoso NS, Haque R et al (2009) Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res 11(6):R85PubMedCrossRef
22.
Zurück zum Zitat Rothman KJ, Greenland S (1998) Modern epidemiology. Lippincott-Raven, Philadelphia Rothman KJ, Greenland S (1998) Modern epidemiology. Lippincott-Raven, Philadelphia
23.
Zurück zum Zitat Latouche A, Porcher R, Chevret S (2004) Sample size formula for proportional hazards modelling of competing risks. Stat Med 23(21):3263–3274PubMedCrossRef Latouche A, Porcher R, Chevret S (2004) Sample size formula for proportional hazards modelling of competing risks. Stat Med 23(21):3263–3274PubMedCrossRef
24.
Zurück zum Zitat Pepe MS, Mori M (1993) Kaplan–Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 12(8):737–751PubMedCrossRef Pepe MS, Mori M (1993) Kaplan–Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 12(8):737–751PubMedCrossRef
25.
Zurück zum Zitat Kalbfleisch JD, Prentice RL (1980) The statistical analysis of failure time data. Wiley, Hoboken Kalbfleisch JD, Prentice RL (1980) The statistical analysis of failure time data. Wiley, Hoboken
26.
Zurück zum Zitat Collins LC, Achacoso N, Nekhlyudov L et al (2009) Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. Am J Surg Pathol 33(12):1802–1808PubMedCrossRef Collins LC, Achacoso N, Nekhlyudov L et al (2009) Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. Am J Surg Pathol 33(12):1802–1808PubMedCrossRef
27.
Zurück zum Zitat Turaka A, Freedman GM, Li T et al (2009) Young age is not associated with increased local recurrence for DCIS treated by breast-conserving surgery and radiation. J Surg Oncol 100(1):25–31PubMedCrossRef Turaka A, Freedman GM, Li T et al (2009) Young age is not associated with increased local recurrence for DCIS treated by breast-conserving surgery and radiation. J Surg Oncol 100(1):25–31PubMedCrossRef
28.
Zurück zum Zitat Rodrigues NA, Dillon D, Carter D, Parisot N, Haffty BG (2003) Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women. Cancer 97(6):1393–1403PubMedCrossRef Rodrigues NA, Dillon D, Carter D, Parisot N, Haffty BG (2003) Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women. Cancer 97(6):1393–1403PubMedCrossRef
29.
Zurück zum Zitat Haque R, Achacoso NS, Fletcher SW et al (2010) Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans. Am J Manag Care 16(5):351–360PubMed Haque R, Achacoso NS, Fletcher SW et al (2010) Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans. Am J Manag Care 16(5):351–360PubMed
30.
Zurück zum Zitat Nassar H, Sharafaldeen B, Visvanathan K, Visscher D (2009) Ductal carcinoma in situ in African-American versus Caucasian American women: analysis of clinicopathologic features and outcome. Cancer 115(14):3181–3188PubMedCrossRef Nassar H, Sharafaldeen B, Visvanathan K, Visscher D (2009) Ductal carcinoma in situ in African-American versus Caucasian American women: analysis of clinicopathologic features and outcome. Cancer 115(14):3181–3188PubMedCrossRef
31.
Zurück zum Zitat Kerlikowske K, Molinaro AM, Gauthier ML et al (2010) Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102(9):627–637PubMedCrossRef Kerlikowske K, Molinaro AM, Gauthier ML et al (2010) Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102(9):627–637PubMedCrossRef
32.
Zurück zum Zitat Rudloff U, Brogi E, Brockway JP et al (2009) Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer 115(6):1203–1214PubMedCrossRef Rudloff U, Brogi E, Brockway JP et al (2009) Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer 115(6):1203–1214PubMedCrossRef
33.
Zurück zum Zitat Adepoju LJ, Symmans WF, Babiera GV et al (2006) Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer 106(1):42–50PubMedCrossRef Adepoju LJ, Symmans WF, Babiera GV et al (2006) Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer 106(1):42–50PubMedCrossRef
34.
Zurück zum Zitat Correa C, McGale P, Taylor C et al (2010) Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010(41):162–177PubMedCrossRef Correa C, McGale P, Taylor C et al (2010) Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010(41):162–177PubMedCrossRef
35.
Zurück zum Zitat Solin LJ, Gray R, Baeher FL, Butler S, Badve S, Yoshizawa C, Shak S, Hughes L, Sledge G, Davidson N, Perez EA, Ingle J, Sparano JA, Wood W (2011) A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): a prospective validation study of the DCIS score from ECOG E5194. Cancer Res 71(24 (Suppl. 1)):108S Solin LJ, Gray R, Baeher FL, Butler S, Badve S, Yoshizawa C, Shak S, Hughes L, Sledge G, Davidson N, Perez EA, Ingle J, Sparano JA, Wood W (2011) A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): a prospective validation study of the DCIS score from ECOG E5194. Cancer Res 71(24 (Suppl. 1)):108S
Metadaten
Titel
Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ
verfasst von
Laura C. Collins
Ninah Achacoso
Reina Haque
Larissa Nekhlyudov
Suzanne W. Fletcher
Charles P. Quesenberry Jr.
Stuart J. Schnitt
Laurel A. Habel
Publikationsdatum
01.06.2013
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2013
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2539-5

Weitere Artikel der Ausgabe 2/2013

Breast Cancer Research and Treatment 2/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.